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Background and objectives: Health economics provides a standardised methodology for valid comparisons
of interventions in different ﬁelds of health care. This review discusses the health economic evaluations
of strategies to enhance blood product safety in sub-Saharan Africa.
Methods: We reviewed health economic methodology with special reference to cost-effectiveness
analysis. We searched the literature for cost-effectiveness in blood product safety in sub-Saharan Africa.
Result: HIV-antibody screening in different settings in sub-Saharan Africa showed health gains and saved
costs. Except for adding HIV-p24 screening, adding other tests such as nucleic acid ampliﬁcation testing
(NAT) to HIV-antibody screening displayed incremental cost-effectiveness ratios greater than the WHO/
World Bank speciﬁed threshold for cost-effectiveness. The addition of HIV-p24 in combination with HCV
antibody/antigen screening and multiplex (HBV, HCV and HIV) NAT in pools of 24 may also be cost-
effective options for Ghana.
Conclusions: From a health economic viewpoint, HIV-antibody screening should always be implemented
in sub-Saharan Africa. The addition of HIV-p24 antigen screening, in combination with HCV antibody/
antigen screening and multiplex (HBV, HCV and HIV) NAT in pools of 24 may be feasible options for
Ghana. Suggestions for future health economic evaluations of blood transfusion safety interventions in
sub-Saharan Africa are: mis-transfusion, laboratory quality and donor management.
 2009 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.1. Introduction
Blood transfusion can be a life saving medical intervention [1].
This is certainly the case in developing countries where conditions
requiring transfusion are often associated with high mortality and
morbidity when transfusion is not available [2]. As with all medical
interventions, blood transfusion not only brings beneﬁts to
patients, but may come at the expense of side-effects ranging from
mild fever to death caused by acute haemolytic reactions [3–5]. The
side-effect that is most often documented in relation to blood
transfusion is the transmission of blood borne infections. Very
important in this respect is the spread of HIV in populations since
the early 1980s. Although the disastrous transmission of HIV in the
era before donor deferral and screening springs to mind, the
disease burden inﬂicted world wide by transfusion-relatedent of Pharmacy, Antonius
Tel.: þ31 50 5247382 or þ31
.
ion for Biologicals. Published by Elhepatitis may surpass that of HIV [6,7]. In the developed world, the
risk of transmission of HIV, hepatitis B virus (HBV) or hepatitis C
virus was greatly reduced over the last decades by donor deferral,
the use of more sensitive screening methods and pathogen
inactivation of plasma derived medicinal products [3,8–12]. The
perception of the risk of blood borne infections and potential
judicial consequences has prompted decision makers to further
maximise transfusion safety with regard to the transmission of
pathogens [13–15]. Currently, bacterial contamination of platelets,
immune system-related side-effects, ﬂuid overload and, last but not
least, transfusion medicine errors pose a greater risk to the health
of patients receiving a blood transfusion in the developed world
than do HBV, HCV or HIV [3,16–18].
Developing countries are faced with speciﬁc problems which
endanger the provision of sufﬁcient safe blood to patients requiring
transfusion [19]. Less than 40% of the donations world wide are
donated in developing countries (low and medium human devel-
opment index; HDI) where more than 80% of the world population
lives. To support the unstable balance between supply and demand
in the blood banks of the developing world, less than 25% of the
donations are from voluntary unpaid regular donors [20]. Mostly,sevier Ltd. All rights reserved.
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members, friends or others, with or without payment [21]. Such
replacement donations have a higher risk of, for example, HIV
infection than the WHO-recommended, unpaid voluntary regular
donors [22]. The main reason that the replacement system has
continued over the last 20 years is that the direct costs are 3–5
times lower compared with the unpaid voluntary regular donor
system [21]. Further increasing the risks, routine screening of
donations for HIV, HBV, HCV and syphilis is not yet fully imple-
mented in all developing countries [20].
2. Principles of cost-effectiveness analysis and health
economics
The methodology of cost-effectiveness analysis and health
economics has been discussed in detail in recent review papers
[23–26]. The main study types used in economic evaluation are
cost-effectiveness (CEA) and cost–utility analysis (CUA) in which
the incremental net costs of a programme are related to the
incremental health beneﬁts.
CEAsmeasure health effects in physical units such as increments
in life-years gained, infections averted, cases found, cases cured,
etc. Cost-minimisation analysis (CMA) is a speciﬁc form of cost-
effectiveness analysis whereby the health effects of the interven-
tion and the current practice are equivalent (or are expected to be
equivalent). In CUA, the incremental life-years gained are adjusted
for quality of life, to arrive at a common measure known as quality
adjusted life-year (QALY). For developing countries, disability
adjusted life-years (DALY) averted are often used as burden of
disease measure. DALYs are estimated by adding the years of life
lost due to the disease and the adjusted years lived with disease.
Costs are measured in monetary units. Cost-effectiveness or cost–
utility ratios are expressed as net costs per unit of effect by
comparing the new interventionwith current practice (incremental
analysis).
Depending on the perspective of a health economic evaluation,
different types of costs are considered. Generally, all health
economic analyses include direct costs for medical care borne by
the health system, community and families of patients. Direct costs
can either be program-related, such as tests in a screening pro-
gramme or can be patient-related, such as hospital, outpatient and
community care. Health economic analyses performed from the
health-care providers’ perspective tend to focus on direct costs
only. The current consensus in health economics is that a more
complete model is achieved with the use of a societal perspective
and therefore that all relevant costs and consequences for society
should be considered, including productivity and leisure losses
[27]. However, discussion remains whether loss of productivity
caused by morbidity and mortality should be incorporated as
indirect costs or as quality adjustments in cost–utility analysis
[28–33], and how to exactly measure indirect costs using human
capital or friction costing approaches. Patient-related costs– direct
as well as indirect– may transfer to beneﬁts if illnesses and related
costs are averted, for example through screening or inactivation
procedures of blood products. The basic concept in health economic
analyses is to evaluate the net costs, i.e. programme costs minus
patient-related beneﬁts. From a health economic viewpoint any
new programmewith negative net cost (offering overall cost saving
programs)– and non-negative health gains– should be
implemented since it is a dominant strategy. Positive net cost
should be related to health gains such as life-years gained. To
determine whether implementation is justiﬁed, the cost-to-health-
gains (cost-effectiveness) ratio should be carefully considered and
compared to acceptability thresholds, if available. The threshold for
health economic acceptability has been published at US$50,000 perQALY gained in the USA [34]. According to WHO and World Bank
guidelines, strategies that show a cost-effectiveness ratio below the
per capita gross national income (GNI) are regarded as cost-effec-
tive, whereas strategies with cost-effectiveness ratio above three
times the per capita GNI are regarded as not cost-effective [35,36].
As viral infections often involve serious complications requiring
complex health-care interventions occurring several years after
infection, the concept of discounting future costs is relevant.
Examples of long-term complications are cirrhosis after years of
chronic hepatitis or development of AIDS in the late stage of HIV
infection. Discounting is a method to adjust future costs and
beneﬁts to their present value (cost and beneﬁts are less weighted
the further in the future they accrue). The discounting procedure
applies two major principles. Firstly, capital invested in a new
technology could have been invested otherwise and may have
gained interest. Secondly, there is a pure time preference with
short-term beneﬁts being preferred to future beneﬁts with respect
to uncertainty as to whether one will be able to beneﬁt from the
monetary amount next year as one is now. The value of the discount
rate should be chosen in accordance with marginal rates on
investment and market interest rates. Many countries use average
interest rates of long-term government bonds [37]. Often, discount
rates are speciﬁed in the national guidelines for health economic
research and vary between, for example, 1.5% for the Netherlands,
3% in the USA, and 6% as previously used in the United Kingdom
[27].
Sensitivity analysis is an important tool to investigate the
outcomes obtained from health economic models. Whereas most
parameters used in the models are derived from clinical trials or
from retrospective data sources, others may be based on individual
expert opinions. Often, few parameters are known with a high
degree of undisputed accuracy. To estimate the effect of uncertain
variables on the robustness of themodel results, sensitivity analysis
is performed.
3. Study characteristics and health economic aspects
We searched MEDLINE for combinations of MESH(sub)-heading
‘‘blood transfusion’’, ‘‘cost(-)effectiveness’’ or ‘‘cost(-)utility’’,
‘‘developing’’, ‘‘Africa’’, ‘‘low-HDI’’. We included health economic
evaluations on blood transfusion safety strategies using outcome
measures expressed in net cost per life-year or per QALY gained,
DALY averted or infections prevented. Additionally, cost(-mini-
misation) analyses that indicate net cost savings were also selected.
Net cost savings do not necessarily require a full health economic
analysis in the absence of negative health gains. Only studies from
sub-Saharan Africa were selected.
The MEDLINE search yielded nine studies that matched our
selection criteria. Unfortunately, two potentially interesting papers;
one on malaria screening [45] and one on HIV screening and
deferral [46], could not be retrieved for full review. In total seven
papers were reviewed (Table 1). HIV screening, only or in combi-
nation with other safety strategies, was the most encountered
subject for health economic evaluation. HIV screening strategies
were evaluated in six out of seven selected papers. Strategies
reducing the risk of HBV or HCV transmission were evaluated in
two studies.
In the early papers, before 2000, the study type was stated as
cost–beneﬁt analysis. Formally, in cost–beneﬁt analysis health
effects are transformed to monetary units. None of the included
studies transformed health gains to monetary units. Also, none of
the selected studies before 2000 used the net costs framework. For
instance, Foster and Buve´ [38] separated the costs of screening for
HIV and the ﬁnancial beneﬁts of preventing HIV infection. The
resulting cost savings of HIV screening were expressed as a beneﬁt
Table 1
Study characteristics and health economic aspects of the selected studies.
Safety strategy Country Year Type Measure Perspective Discounting
M (%) H (%)
HIV screening [38] Zambia 1991 CEA US$/LYG Health care 3 0
HIV screening [39] Zaire 1992 CEA US$/IP Health care n.i. n.i.
HIV screening, more voluntary donations,
reducing transfusions, autologous
transfusions, laboratory quality [40]
Tanzania 1992 CA US$ Health care 5 5
HCV screening [41] Uganda 1999/2000 CEA US$/IP n.i. n.r. n.r.
HIV screening [42] Chad 1999 CEA US$/IP n.i. n.i. n.i.
HIV screening [43] Ghana 2004 CUA US$/DALY Societal 3 3
HBV, HCV and HIV screening [44] Ghana 2007 CUA US$/DALY Health care 3 3
Abbreviations: CA, cost analysis; CEA, cost-effectiveness analysis; CUA, cost–utility analysis; HCV, hepatitis C virus; H, health; HIV, human immunodeﬁciency virus; IP,
infection prevented; LYG, life-year gained; M, monetary; n.i., not included; n.r., not required because of short-term time frame.
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societal perspective in the analysis. The perspective of the health-
care provider was themost utilised viewpoint (four out of seven). In
two papers the perspective was not speciﬁed or could not be
determined from the paper.
Univariate and/or multivariate sensitivity analysis was carried
out in six out of seven studies. Discounting of costs was performed
in four of seven health economic evaluations. In three out of the
seven analyses, health beneﬁts were discounted.
4. Results
All papers reporting on the cost-effectiveness of post-donation
HIV-antibody screening in sub-Saharan Africa show that HIV
screening gives health gains and saves costs (Table 2). New HIV
infections prevented by HIV-antibody screening ranged from 150 toTable 2
Risk reduction and health economic implications of improving blood transfusion safety.
Safety strategy Country Year Risk
interventiona
HIV screening [38] Zambia 1991 106
HIV screening [39] Zaire 1992 n.s.
HIV more voluntary donations,
reducing transfusions, autologous
transfusions, laboratory quality [40]
Tanzania 1992 64
HIV screening þmore voluntary donations,
reducing transfusions, autologous
transfusions, laboratory quality [40]
Tanzania 1992 64
HCV screening [41] Uganda 1999/2000 n.s.
HIV screening [42] Chad 1999 78
HIV-Ab vs no screening [43] Ghana 2004 2.76
HIV-p24 vs Ab [43] Ghana 2004 2.04
HIV MP24-NAT vs p24 [43] Ghana 2004 1.22
HIV ID-NAT vs MP24-NAT [43] Ghana 2004 0.76
HIV-p24, þ HCVAgAb þ HBsAg
vs HIV-Ab þ HCV-Ab HBsAg [44]
Ghana 2007 n.s.e
MP24 multiplex NAT vs HIV-p24,
þ HCVAgAb þ HBsAg [44]
Ghana 2007 n.s.e
MP6 multiplex NAT vs MP24
multiplex NAT [44]
Ghana 2007 n.s.e
ID multiplex NAT vs MP6
multiplex NAT [44]
Ghana 2007 n.s.d
Abbreviations: Ab, antibody; BCR, beneﬁt to cost ratio; HBV, hepatitis B virus; HCV, he
minipool of 6 or 24 donations; n.i., not included; n.s., not speciﬁed.
a Per 10,000 donations.
b Reduction of transfused patients (from 3000 to 1200) gave extra reduction of HIV tr
c Similar costs were assigned by the authors.
d Crude HIV transmission risk was 1200 per 10,000 donations before introduction o
transfusions, laboratory quality.
e Parameters can be found at http://www.bloodsafety.info.1400 per 10,000 donations. Obviously, the number of new HIV
infections prevented depended strongly on the HIV prevalence in
blood donors and the prevalence of HIV infection in transfusion
recipients. The incremental cost of HIV-antibody screening seems
to have decreased over the last decade, improving the health
economic proﬁle of HIV-antibody screening even further.
Only two health economic evaluations were found which eval-
uated the use of more sensitive HIV antigen tests, such as p24 or
NAT, in addition to HIV-antibody screening in sub-Saharan Africa.
Both evaluations were carried out in Ghana and conducted by the
authors of this review. One evaluating multiplex screening for HBV,
HCV and HIV will be discussed later. The number of new HIV
infections prevented by p24, NAT in minipools of 24 samples
(MP24-NAT) and individual donation NAT (ID-NAT) in addition to
HIV-antibody screening were 0.7,1.5 and 1.95 per 10,000 donations,






1892 1398 4.42 Cost saving, BCR 2.7/1
265–529 n.s. 9.12–18.56 171–349 US$ test costs/
prevented HIV þ donation
98 155b 12.41d Cost saving, BCR ranging
from 3.1/1 to 6.6/1
801c 864b 12.41d Cost saving, BCR ranging
from 16/1 to 37/1
58 62–77 5.95 782–938 US$ per HCV
infection prevented
778 1400 12.23 87 US$ per HIV infection
prevented
151 241 5 Cost saving, BCR 10/1
2.76 0.7 2 1237 US$/DALY averted
2.04 1.5 5.5 2248 US$/DALY averted
1.22 1.95 7.5 3508 US$/DALY averted
n.s.e 1.41 (HIV) 2.18 (HCV) 1.60 608 US$/DALY averted
n.s.e 1.59 (HIV) 0.24 (HCV)
0.00 (HBV)
16.40 1154 US$/DALY averted
n.s.e 0.42 (HIV) 0.06 (HCV)
0.95 (HBV)
13.00 2468 US$/DALY averted
n.s.d 0.48 (HIV) 0.06 (HCV)
0.12 (HBV)
24.60 8306 US$/DALY averted
patitis C virus; HIV, human immunodeﬁciency virus; ID, individual donation; MP,
ansmission.
f HIV screening and more voluntary donations, reducing transfusions, autologous
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10,000 donations. In combination with the high additional cost of
the more sensitive tests and the low yield of prevented HIV
transmissions, the resulting incremental cost-effectiveness ratios
(ICERs) are relatively high compared to HIV-antibody screening. In
2008 the GNI per capita of Ghana was US$670 (US$480 in 2004)
[47,48]. Therefore, the World Bank/WHO threshold for cost-effec-
tiveness (three times the GNI per capita) was US$2010 in 2008
(US$1440 in 2004). Only HIV-p24 antigen screening was below the
speciﬁed threshold for cost-effectiveness for Ghana in 2004.
Very few data are available on the cost-effectiveness of
screening blood donations for viruses other than HIV in sub-
Saharan Africa. For Uganda it was estimated that HCV screening of
blood donation would cost US$782–938 per new HCV infection
prevented. However, saved health-care costs by preventing HCV
infection were not included in this study.
Using a health economic model which is accessible by a Web
interface (http://www.bloodsafety.info), the residual risk of trans-
mission and the cost of screening were estimated for ﬁve post-
donation screening strategies for Ghana [44]:
(1) HBsAg, HCV-Ab, and HIV-Ab;
(2) HBsAg, HCV-Ab þ Ag (HCV combo), and HIV-Ab þ p24 (HIV
combo);
(3) MP24-NAT (pool of 24 donations on HBV, HCV, and
HIV) þ HIV-Ab, HCV-Ab, and HBsAg;
(4) MP6-NAT (pool of six donations on HBV, HCV, and HIV) þ HIV-
Ab, HCV-Ab, and HBsAg; and
(5) ID-NAT (on HBV, HCV, and HIV) þ HIV-Ab, HCV-Ab, and HBsAg.
Strategies were compared to the next least expensive strategy,
for instance (2) versus (1), (3) versus (2), (4) versus (3), etc.
Compared to HIV-p24 screening alone, the combination of this test
with HCV combo seems to be a more cost-effective strategy. Also,
multiplex (HBV, HCV and HIV) minipool NAT screening in pools of
24 seems to be more cost-effective than HIV MP24-NAT alone. Both
strategies (2 and 3) were also below the World Bank/WHO three
times the GNI per capita threshold for cost-effectiveness of
US$2010 in 2008.
5. Discussion
Blood donation screening for HIV-antibody to prevent HIV
infection in sub-Saharan Africa is a strategy which saves costs and
provides health gains [38]. Therefore, from a health economic
viewpoint, HIV-antibody screening should always be implemented.
Similar to high-HDI countries, more sensitive tests added to HIV-
antibody, HCV antibody and HBsAg screening are generally asso-
ciated with higher ICERs. More than three times the GNI or GDP per
capita is needed to save one DALY for MP6 and ID-NAT. However,
compared to high-HDI countries, the ratio of GNI or GDP to the
cost-effectiveness ratio is considerably lower. The ratio of the ICER
to the GNI of IDmultiplex NATcompared toMP6multiplex NATwas
18.5 versus over 1600 for Ghana and the Netherlands, respectively
[44]. This difference is explained by the young average age of the
transfusion recipient and, obviously, the higher risk of viral trans-
mission. Using NAT in addition to serological screening for HBV,
HCV HIV is probably not cost-effective for Ghana, although multi-
plex MP24-NAT may be an exception. Moreover, using NAT in blood
bank screening was also not shown to be cost-effective to enhance
HIV screening in a cross-section of African countries [49]. Antigen
screening used in combinationwith antibody screening for HIV and
HCV may be a cost-effective option for some countries.
Blood supply systems in high-HDI countries provide a very high
level of product safety with regard to transfusion transmittedinfection. Implementing these systems in developing countries
appears to be an attractive solution to improve blood transfusion
[50]. However, we must remember that the costs of achieving such
systems and maintaining these levels of safety in developed
countries are very high. The societal cost of transfusing two units of
RBC in The Netherlands (US$400–500) exceeds the GNI per capita
in the majority of the low-HDI countries. Blood supply systems in
developing countries are gradually moving from hospital-based
blood banks, heavily dependent on replacement donors, to more
consolidated and nationally supported systems relying on volun-
tary donors. In general, the unit costs of blood products from
consolidated blood supply systems are higher than those from
hospital-based blood banks [51]. Most consolidated blood supply
systems in African countries receive external funding [51]. The
dependence on external funding hampers the sustainability of
these consolidated blood supply systems. Preliminary data showed
that an alternative hospital-based screening strategy using pre-
donation rapid test screening in combinationwithminipool NATon
HBV, HCV and HIV may be cost-effective [52]. Pre-donation rapid
tests for HBV, HCV and HIV in combinationwith post-donation NAT
cost less and prevent more loss of health than post-donation
serological screening.
The contribution of human error to the risk of pathogen trans-
mission is reported to be very low in high-HDI countries [53]. In
low-HDI countries, however, what little data there are, indicate that
human error can contribute up to 20% of the HIV transmission risk
[54,55]. An overview of interventions improving transfusion safety
in a selection of African countries revealed that interventions
reducing human error in screening and processing of blood dona-
tions were cost-effective [49]. Because of the lack of data on human
error, we designed a prospective study to investigate the contri-
bution of human error to pathogen transmission in low-HDI
countries [56]. The study yielded useful and interesting observa-
tions, although the original goals of the research plan were not
reached. We found that infectious disease marker screening was
not performed within the required time after blood donation.
Furthermore, collection and storage conditions of samples were not
according to speciﬁcations. Also, volume variations, poor labelling
and haemolysis of the blood samples were noted. Nevertheless, the
problems encountered do also indicate that human error
augmented by absence of a working quality system will contribute
to pathogen transmission in low-HDI countries.
Enhancing blood transfusion safety in low-HDI countries by
introducing more sensitive high-tech tests is maybe not cost-
effective. Nevertheless, transfusion recipients in low-HDI countries,
who are mainly children and young women, face a substantially
higher probability of HBV, HCV and HIV infection compared to
transfusion recipients in high-HDI countries. From the papers
included in this review, directions for cost-effective improvements
in transfusion safety in low-HDI countries can be discerned. For
some regions it may be worthwhile to investigate whether pre-
donation screening in combination with in-house NAT is cost-
effective. Preliminary data indicate that investments in donor
management to motivate low-risk voluntary non-remunerated
donors to donate blood are cost-effective. Also, investments in
laboratory performance and quality systems to achieve a reduction
of human error may prevent considerable disease burden in
transfusion recipients [57]. Overall, however, the inadequate supply
of safe blood is regarded as the greatest threat to blood transfusion
safety in low-HDI countries [20].
6. Future perspectives
The cost-effectiveness of preventing transfusion transmitted
HBV, HCV and HIV infection with screening is well studied in
M. van Hulst et al. / Biologicals 38 (2010) 53–58 57high-HDI countries. However, health economic evaluation is still
needed to provide decision makers with insights into the costs and
consequences of adopting new screening strategies for emerging
pathogens [58–60]. Health economics of donor-related interven-
tions, such as temporary exclusion or motivating speciﬁc low-risk
donor groups to donate, are scarce and more research is warranted
in this important area of blood transfusion safety [61,62]. Health
economic evaluations can also be used when new technology to
inactivate pathogens in red blood cell concentrates or whole blood
becomes available [63]. Currently, transfusing the wrong unit to the
wrong patient causes the greatest disease burden in The
Netherlands and other developed countries [64–66]. Also for
developing countries mis-transfusion may contribute to a high
disease burden. Health economic evaluations of available measures
to prevent these mis-transfusions in developing countries, such as
wristband patient identiﬁcation, could motivate decision makers to
develop legislation and make funds available to introduce these
safety barriers in clinical practice [67,68]. For low- to medium-HDI
countries, further research in the health economics of improving
blood transfusion safety by screening strategies for HBV, HCV and
HIV is needed to inform decision makers. Special attention should
be given in these evaluations to the sustainability and technical
feasibility of the proposed screening strategies. Sustainability and
affordability should also be considered from the perspective of the
payer, which is often the family of the patient in low-HDI countries.
Health economics of donor-related interventions, such as using
donor management to motivate regular voluntary non-remuner-
ated donors, is of particular importance in low-HDI countries.
Preliminary data showed that room for improvement exists in
laboratory standards [57]. The quality of blood grouping performed
in the blood bank laboratory is as essential for the safety of the
blood transfusion as screening donations for pathogens. The costs
and consequences of replacing error prone manual blood grouping
by more sophisticated techniques in low-HDI countries may be
worthy of exploration.
As science progresses and new evidence comes available,
economic models require updating. The time to publication of the
results of a health economic evaluation is considerable. Often,
estimates used in the health economic evaluation quickly become
outdated, thus invalidating the results of the health economic
evaluation. Sometimes, updates of health economic evaluations
appear as brief reports which lack sufﬁcient detail for proper
interpretation. These problems can be overcome by disseminating
health economic evaluations on the internet as well as in peer-
review journals. In fact, all peer-reviewed journals should stimulate
authors to publish their models with associated technical appen-
dices online, in order to promote the transparency of health
economic models. Often, health economic models are regarded as
a ‘black box’. Online publication of health economic models
enhances transparency since the quality of the models can be
scrutinised by peers.
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